Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Reduced by Sandy Spring Bank

Sandy Spring Bank cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 73.3% during the fourth quarter, HoldingsChannel.com reports. The firm owned 64 shares of the biopharmaceutical company’s stock after selling 176 shares during the period. Sandy Spring Bank’s holdings in Regeneron Pharmaceuticals were worth $56,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Fortitude Family Office LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $31,000. Sutton Wealth Advisors Inc. lifted its stake in Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 13 shares during the last quarter. Finally, Bruce G. Allen Investments LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $40,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $904.70 on Friday. The stock has a market cap of $99.30 billion, a P/E ratio of 26.03, a PEG ratio of 2.64 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The company has a fifty day moving average price of $957.56 and a 200 day moving average price of $889.10. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the company earned $10.96 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph L. Goldstein sold 2,707 shares of the business’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the completion of the sale, the director now directly owns 6,382 shares in the company, valued at approximately $6,062,900. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock valued at $13,124,641 in the last 90 days. 8.83% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on REGN. Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. Truist Financial reiterated a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Cantor Fitzgerald lifted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the company a “neutral” rating in a research note on Tuesday, February 6th. Bank of America boosted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday. Finally, Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. One analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $970.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.